Preclinical studies show that targeting molecules participating in cellular attachments including integrins, adapter proteins, and associated kinases can be proposed as a promising strategy to increase the sensitivity of cancer cells to chemotherapy and radiotherapy as well as development of synthetic lethal approaches by multi‐targeting in combination with radio‐chemotherapy in future.42 The gene discussed is TOLLIP; the disease is cancer.